Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: A multicentre phase II study

Lung Cancer

Volumn 50, Issue 1, 2005, Pages 115-122

  Ziotopoulos, Panagiotis ^a   Androulakis, Nikolaos ^a   Mylonaki, Efthimia ^a   Chandrinos, Vassilios ^a   Zachariadis, Emmanouel ^a   Boukovinas, Ioannis ^a   Agelidou, Athina ^a   Kentepozidis, Nikolaos ^a   Ignatiadis, Michail ^a   Vossos, Andreas ^a   Georgoulias, Vassilis ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Docetaxel; Irinotecan; NSCLC; Phase II trial

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ATROPINE; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; IRINOTECAN; LOPERAMIDE; OCTREOTIDE; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE CHOLINERGIC SYNDROME; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MOTOR DYSFUNCTION; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 24744439246     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.05.004     Document Type: Article

References (31)

1. Non-Small Cell Lung Cancer Collaboration Group. Chemotherapy in NSCLC: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-904.
2. P. Kosmidis, N. Mylonakis, C. Nicolaides, C. Kalophonos, E. Samantas, and J. Boukovinas Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non small cell lung cancer. A phase III randomized trial J. Clin Oncol 20 2002 3578 3585
3. V. Georgoulias, E. Papadakis, A. Alexopoulos, X. Tsiafaki, A. Rapti, and M. Veslemes Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: A randomized multicenter trial Lancet 357 2001 1478 1484
4. E.F. Smit, J.P.A.M. van Meerbeck, P. Lianes, C. Debruyne, C. Legrand, and F. Schramel Thress-arm randomized study if two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: A phase II trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975 J. Clin Oncol 21 2003 3909 3917
5. C. Gridelli, C. Gallo, F.A. Shepherd, A. Illiano, F. Piantedosi, and S.F. Robbiati Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 121 2003 3025 3034
6. F.V. Fossella, J.S. Lee, W.K. Murphy, S.M. Lippman, M. Calayag, and A. Pang Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer J Clin Oncol 12 1994 1238 1244
7. H.A. Burris, J. Eckardt, S. Fields, G. Rodriguez, L. Smith, and A. Thurman Phase II trials of Taxotere in patients with non-small cell lung cancer Proc Am Soc Clin Oncol 12 1993 335 [abstract]
8. Berille J, Le Chevalier T, Zalcberg JR, Millward MJ, Monnier A, Douillard JY, et al. Overview on Taxotere-cisplatin (TXT/CDDP) combination in non-small cell lung cancer (NSCLC). Ann Oncol 1996;7L (Suppl. 5):90 [abstract].
9. N. Masuda, M. Fukuoka, Y. Kusunoki, K. Matsui, N. Takifuji, and S. Kudoh CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer J Clin Oncol 10 1992 1225 1229
10. M.L. Rothenberg CPT-11: an original spectrum of clinical activity Semin Oncol 23 1, Suppl. 3 1996 21 26
11. C.J. Langer The global role of irinotecan in the treatment of lung cancer: 2003 update Oncology 17 Suppl. 7 2003 30 40
12. K. Okishio, S. Kudoh, and K. Hirata Schedule dependent additive effect of docetaxel and irinotecan in vitro Proc JPN J Cancer Res 86 1995 619 [abstract 2252]
13. X.H. Pei, Y. Nakanishi, K. Takayama, F. Bai, M. Kawasaki, and N. Tsuruta Effect of CPT-11 in combination with other anticancer agents in lung cancer cells Anticancer Drugs 8 1997 231 237
14. Y. Kano, M. Akutsu, S. Tsunoda, K. Mori, K. Suzuki, and K.I. Adachi In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines Cancer Chemother Pharmacol 42 1998 91 98
15. A.A. Adjei, C.E. Klein, H. Kastrissios, R.M. Goldberg, S.R. Alberts, and H.C. Pitot Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: Preliminary evidence of clinical activity J. Clin Oncol 18 2000 1116 1123
16. A.B. Miller, B. Hoogstraten, and M. Staquet Reporting results of cancer treatment Cancer 47 1981 207 214
17. E.L. Kaplan, and P. Meier Non-parametric estimation from incomplete observation J. Am Stat Assoc 53 1959 457 481
18. D.R. Cox The Analysis of Binary Data 1970 Methuen London, United Kingdom
19. C. Couteau, F. Rokiec, L. Vermillet, J. Santoni, P. Baille, and D. Borrits Phase I dose-finding and pharmacokinetic study of docetaxel in combination with irinotecan in advance solid tumors Proc Am Soc Clin Oncol 16 1997 202a [abstract]
20. N. Masuda, S. Negoro, S. Kudoh, T. Sugiura, K. Nakagawa, and H. Saka Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer J. Clin Oncol 18 2000 2996 3003
21. N. Nogami, S. Harita, S. Ueoka, T. Yonei, K. Kiura, and H. Kamei Phase I study of docetaxel and irinotecan in patients with advanced non-small cell lung cancer Lung Cancer 45 2004 85 91
22. T.C. Chou, R.J. Motzer, Y. Tong, and G.J. Bosl Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design J Natl Cancer Inst 86 1994 1517 1524
23. S.H. Kaufmann, D. Peereboom, G.A. Buckwalter, P.A. Svingen, L.B. Grochow, and R.C. Donehower Cytotoxic effects of topotecan combinated with various anticancer agents in human cancer cell lines J. Natl Cancer Inst 88 1996 734 741
24. K. Hotta, H. Ueoka, K. Kiura, M. Tabata, S. Kuyama, and K. Satoh A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer Lung Cancer 45 2004 77
25. N. Yamamoto, M. Fukuoka, S. Negoro, K. Nakagawa, H. Saito, and K. Matsui Randomized phase II study of docetaxel/cisplatin vs. docetaxel/irinotecan in advanced non-small cell lung cancer A West Japan Thoracic Oncology Group study (WJTOG) Br J Cancer 90 2004 87 92
26. S. Ramalingam, T.W. Dobbs, D.E. Coke, S. Wojtowicz-Praga, and C.P. Belani Weekly docetaxel and irinotecan for patients with advanced non-small cell lung cancer (NSCLC): results of a multi-center, phase II study Proc Am Soc Clin Oncol 22 2004 690s [abstract 7298]
27. D. Pectasides, A. Visvikis, A. Kouloubinis, J. Glotsos, N. Bountouroglou, and N. Karvounis Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study Eur J Cancer 38 2002 1194 1200
28. F.M. Wachters, H.J.M. Groen, B. Biesma, F.M. Schramel, P.E. Postmus, and J.A. Stigt A randomized phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIB-IV non-small cell lung cancer who failed first-line treatment Br J Cancer 92 2005 15 20
29. F. Grossi, O. Belvedere, C. Rossetto, A. Sibau, E. Vigevani, and L. Recchia Irinotecan plus docetaxel in previously treated non-small cell lung cancer (NSCLC): an Alpe Adria Thoracic Oncology Multidisciplinary group phase II study (ATOM 007) Proc Am Soc Clin Oncol 22 2004 706s [abstract 7363]
30. R.S. Keresztes, M. Socinski, P. Bonomi, A. Chen, L. Hart, and R. Lilenbaum Phase II randomized trial of irinotecan/docetaxel (ID) or irinotecan/gemcitabine (IG) with or without celecoxib (CBX) in second-line treatment of non-small-cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 22 2004 650s [abstract 7137]
31. J.R. Sande, J. Verdirame, S. Hillman, S. Geyer, T. Drevyanko, and H. Tazelaar A phase II study of irinotecan and docetaxel in patients with recurrent non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 21 2002 324a [abstract 1295]